HK1012267A1 - Use of topotecan in the treatment of non-small cell lung carcinoma - Google Patents
Use of topotecan in the treatment of non-small cell lung carcinomaInfo
- Publication number
- HK1012267A1 HK1012267A1 HK98113537A HK98113537A HK1012267A1 HK 1012267 A1 HK1012267 A1 HK 1012267A1 HK 98113537 A HK98113537 A HK 98113537A HK 98113537 A HK98113537 A HK 98113537A HK 1012267 A1 HK1012267 A1 HK 1012267A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- small cell
- cell lung
- lung carcinoma
- topotecan
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65893791A | 1991-02-21 | 1991-02-21 | |
PCT/US1992/001034 WO1992014471A1 (en) | 1991-02-21 | 1992-02-07 | Treatment of non-small cell lung carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1012267A1 true HK1012267A1 (en) | 1999-07-30 |
Family
ID=24643331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK98113537A HK1012267A1 (en) | 1991-02-21 | 1998-12-15 | Use of topotecan in the treatment of non-small cell lung carcinoma |
Country Status (14)
Country | Link |
---|---|
US (1) | US5756512A (es) |
EP (1) | EP0572549B1 (es) |
JP (1) | JP2738979B2 (es) |
KR (1) | KR930702984A (es) |
AT (1) | ATE227991T1 (es) |
AU (2) | AU1531992A (es) |
CA (1) | CA2103707C (es) |
DE (1) | DE69232852T2 (es) |
DK (1) | DK0572549T3 (es) |
ES (1) | ES2187500T3 (es) |
HK (1) | HK1012267A1 (es) |
MX (1) | MX9200755A (es) |
PT (1) | PT100155B (es) |
WO (1) | WO1992014471A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997019085A1 (en) * | 1995-11-22 | 1997-05-29 | Research Triangle Institute | Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties |
US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US6228855B1 (en) | 1999-08-03 | 2001-05-08 | The Stehlin Foundation For Cancer Research | Aromatic esters of camptothecins and methods to treat cancers |
US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
-
1992
- 1992-02-07 WO PCT/US1992/001034 patent/WO1992014471A1/en active IP Right Grant
- 1992-02-07 AT AT92907467T patent/ATE227991T1/de not_active IP Right Cessation
- 1992-02-07 DK DK92907467T patent/DK0572549T3/da active
- 1992-02-07 DE DE69232852T patent/DE69232852T2/de not_active Expired - Fee Related
- 1992-02-07 JP JP4507270A patent/JP2738979B2/ja not_active Expired - Fee Related
- 1992-02-07 EP EP92907467A patent/EP0572549B1/en not_active Expired - Lifetime
- 1992-02-07 CA CA002103707A patent/CA2103707C/en not_active Expired - Fee Related
- 1992-02-07 ES ES92907467T patent/ES2187500T3/es not_active Expired - Lifetime
- 1992-02-07 AU AU15319/92A patent/AU1531992A/en not_active Abandoned
- 1992-02-07 KR KR1019930702491A patent/KR930702984A/ko not_active Application Discontinuation
- 1992-02-21 MX MX9200755A patent/MX9200755A/es unknown
- 1992-02-21 PT PT100155A patent/PT100155B/pt not_active IP Right Cessation
-
1995
- 1995-12-14 AU AU40427/95A patent/AU699436B2/en not_active Ceased
-
1996
- 1996-07-16 US US08/699,046 patent/US5756512A/en not_active Expired - Fee Related
-
1998
- 1998-12-15 HK HK98113537A patent/HK1012267A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69232852D1 (de) | 2003-01-02 |
WO1992014471A1 (en) | 1992-09-03 |
MX9200755A (es) | 1992-08-01 |
US5756512A (en) | 1998-05-26 |
KR930702984A (ko) | 1993-11-29 |
AU699436B2 (en) | 1998-12-03 |
AU4042795A (en) | 1996-02-22 |
DK0572549T3 (da) | 2003-01-06 |
JPH06505741A (ja) | 1994-06-30 |
PT100155A (pt) | 1993-05-31 |
PT100155B (pt) | 1999-09-30 |
ATE227991T1 (de) | 2002-12-15 |
JP2738979B2 (ja) | 1998-04-08 |
CA2103707C (en) | 2003-12-09 |
EP0572549A4 (es) | 1994-01-12 |
EP0572549A1 (en) | 1993-12-08 |
ES2187500T3 (es) | 2003-06-16 |
AU1531992A (en) | 1992-09-15 |
EP0572549B1 (en) | 2002-11-20 |
CA2103707A1 (en) | 1992-08-22 |
DE69232852T2 (de) | 2003-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1012268A1 (en) | Composition containing cisplatin and topotecan as antitumor agent | |
ATE105482T1 (de) | Behandlung von krebs mit somatostatin und mit analogen davon. | |
IE900250L (en) | Immunogenic compositions against gastrin peptides | |
ZA932455B (en) | Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent | |
HK1022810A1 (en) | Method of treating endothelial injury | |
MY106528A (en) | Method of treating impotence. | |
DE3478749D1 (en) | Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism | |
HK1012267A1 (en) | Use of topotecan in the treatment of non-small cell lung carcinoma | |
DE3569673D1 (en) | Use of saccharomyces yeasts for the manufacture of a medicament for preventing or treating pseudo-membranous colitis | |
GB2098478B (en) | Propioibacteria preparations for use in the treatment of tumours | |
HK1006947A1 (en) | Treatment of liver cancer | |
IL131478A0 (en) | Methods for treatment of scar tissue | |
CA2103708A1 (en) | Treatment of ovarian cancer | |
ES2012547A6 (es) | Procedimiento para preparar una composicion farmaceutica que contiene metaloporfirinas. | |
KR0177821B1 (en) | Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans | |
IL89998A0 (en) | Use of gonadoliberin derivatives in the treatment of tumours | |
EP0278715A3 (en) | Use of human gamma interferon for treatment of basal cell carcinoma | |
GB2188312B (en) | Improvements in or relating to the treatment of waters | |
AR244180A1 (es) | Mejoras en dispositivos para el tratamiento de agua, con gases oxidantes producidos ''in situ''. | |
GB8818556D0 (en) | Novel therapeutic immunoconjugates for use in treatment of cancer | |
BG34201A1 (en) | Method for potentiating the effect of cytostatic agents in chemical treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20100207 |